A recent remarkable success of treating advanced cancer with immune check-point inhibitors (ICIs) highlight important roles that programmed cell death protein-1 (PD-1) and cytotoxic T lymphocyte-associated protein-4 (CTLA-4) play in the suppression of anti-cancer immune responses [1, 2]. This evidence concerns the gene CTLA4 and cancer.